Progress in Mind

Improved treatment and a better life for people with psychiatric and neurological disorders.

More than 700 million people are affected by psychiatric and neurological disorders worldwide – this is equal to 13% of the global disease burden1. Progress in Mind is Lundbeck’s dedication to addressing the global burden of psychiatric and neurological disorders.

Our foundation for progress
Psychiatric and neurological disorders are defined as a global health problem2. Through improved medical treatments and continuous focus on the unmet needs of patients, we want to address the issue and call for greater awareness of the massive economic and societal burden psychiatric and neurological disorders represents.

With our unique position as a specialist in psychiatry and neurology, we want to raise disease awareness and challenge the international agenda for broader acceptance of patients and increased opportunities for better treatment. 

Far too many people suffer from psychiatric and neurological disorders. At Lundbeck, we ask why...

Why do more than 700 million people in the world have to live with psychiatric and neurological disorders?3
Why do almost 50% of people with psychiatric and neurological disorders not receive any treatment?4
Why should people with psychiatric and neurological disorders live 10-20 years less than others?5
Why do more than 70% of people living with psychiatric and neurological disorders experience discrimination?6
Why is it that 90% of all suicide victims suffered from a psychiatric and neurological disorders?7

Our involvement
Global progress for people living with psychiatric and neurological disorders requires a multifaceted approach. First and foremost, we continue to develop new and improved medical treatments and continue to focus on the patient, ensuring that he or she regains possibilities. But we also work to embrace our vision from two other essential dimensions: We encourage increased support to affected families and we engage in communities to create broader social acceptance of patients.

To raise awareness and prevent stigmatization, we use our voice as specialists in psychiatry and neurology and share our knowledge about the many unmet needs in the treatment of psychiatric and neurological disorders. We reach into both professional and patient communities to offer disease education and support programmes to health care professionals, patients and their families. Our global presence enables us to let successful, local initiatives travel the world and make a difference to patients everywhere.

Our R&D commitment
Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Together with our partners, we make our drugs available across continents for the benefit of millions of patients.

Meeting unmet needs of patients
Our specialists develop new drugs on the basis of deep insight into the brain, the specific diseases, and into the unmet needs of the patients. In order to create successful treatments, a dedication to the patient and his or her specific needs is crucial and precedes any development phase in Lundbeck’s R&D commitment. Understanding patients’ treatability and individual disease progression, as well as experienced symptoms, and side effects to current treatments, represents the most important driving force behind Lundbeck’s neuroscience research and enables us to develop tomorrow’s drugs.

References

  1. http://www.ifpma.org/wp-content/uploads/2016/01/2012_IFPMA_Position_Paper_on_MNDs.pdf, http://www.who.int/mediacentre/factsheets/fs396/en/, http://www.who.int/features/qa/55/en/index.html
  2. WHO Quality Rights Project – addressing a hidden emergency, 2011
  3. http://www.ifpma.org/fileadmin/content/Global%20Health/Mental_Health/2012_IFPMA_Position_Paper_on_MNDs.pdf, http://www.who.int/mediacentre/factsheets/fs396/en/, http://www.who.int/features/qa/55/en/index.html
  4. http://www.oecd.org/els/soc/49227189.pdf
  5. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Osby U, Correia N, Brandt L, Ekbom A, SpareĢn P. Schizophr Res. 2000;45(1–2):21–8
  6. http://blog.ted.com/2012/09/11/some-stats-on-the-devastating-impact-of-mental-illness-worldwide-followed-by-some-reasons-for-hope/, http://www.time-to-change.org.uk/what-are-mental-health-problems/stigma-discrimination
  7. http://depts.washington.edu/mhreport/facts_suicide.php, https://www.nami.org/Learn-More/Mental-Health-Conditions/Related-Conditions/Suicide, http://who.int/mental_health/suicide-prevention/world_report_2014/en/, http://journals.cambridge.org/download.php?file=%2FPSM%2FPSM33_03%2FS0033291702006943a.pdf&code=6e086fc0f55440640244640216120c97 

Progress in Mind brochure

Download our Progress in Mind brochure and learn about Lundbeck and our dedication to improving treatment and a better life for people living with psychiatric and neurological disorders. 

Download PDF

VIDEO

The Lundbeck Movie

The burden of psychiatric and neurological disorders is growing and we ask WHY.

Understanding brain disease

Visit our corporate YouTube channel where we have gathered a number of videos about mental health and psychiatric and neurological disorders in general, but also about depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. 

Expand your knowledge

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.